Meeting
2019 Gastrointestinal Cancers Symposium
Adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunostaining in curative resected pancreatic adenocarcinoma: A biomaker stratified trial.
Authors
Dong Woo Shin
Seoul National University Bundang Hospital, Seoul, Korea, Republic of (South)
Dong Woo Shin , Min Jae Kim , Se Yeol Yang , Jong-chan Lee , Jin-Hyeok Hwang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02486497
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 308)
DOI
10.1200/JCO.2019.37.4_suppl.308
Abstract #
308
Poster Bd #
G6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).
First Author: Fergus Keane
Poster
2021 Gastrointestinal Cancers Symposium
Gastric and gastroesophageal adenocarcinoma survival outcomes relative to completion of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A single-center retrospective analysis.
First Author: Michael J Allen
Poster
2019 Gastrointestinal Cancers Symposium
Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).
First Author: Changhoon Yoo
Poster
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi